CELLULAR MECHANISMS OF TRAUMATIC BRAIN INJURY & CONCUSSION
With
Professor Melinda (Lindy) Fitzgerald, Deputy Vice Chancellor, Research & Professor of Neurotrauma, Curtin University, Western Australia John Curtin Distinguished Professor & CEO Connectivity Traumatic Brain Injury Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor Melinda Fitzgerald is Deputy Vice Chancellor, Research at Curtin University, John Curtin Distinguished Professor and CEO of Connectivity Traumatic Brain Injury Australia.
She has published over 135 papers; recent highlights include Lancet Neurology, J Neuroscience, Nature Nano, ACS Nano, Biomaterials. Currently held grants/Projects total $10.1 million; CIA for $5.2 million of these; $18.5 million total research and equipment funding, $9.9 million as CIA; continuous category 1 grant funding as CIA since 2009.
Prof Fitzgerald was Ministerially appointed and re-appointed as Chair and Co-Chair of the Expert Working Group of the Federal Government MRFF Mission for TBI, 2019 and 2024 ($50m over 10 years).
Prof Fitzgerald is a Member of the Executive Committee for International TBI Research (InTBIR2) and Co-Chair of the InTBIR2 Working Group on Observational and Comparative Effectiveness Studies.
She has supervised more than 35 Honours students or equivalent, 20 PhD students (14 completions), and 12 post-doctoral researchers (5 currently); of whom 3 are Group Leaders and 15 are developing independent scientific and research careers.
As CEO of Connectivity Traumatic Brain Injury Australia, Prof Fitzgerald has led dissemination of best practice knowledge to the community. Connectivity’s work on raising awareness of traumatic brain injury has been viewed more than 6.93 million times, including 255,000 individual users of the website and more than 641,000 views on YouTube, accessing research-informed, best practice evidence-based information about concussion and more severe traumatic brain injury, including 110,000 views of our Aboriginal and Torres Strait Islander prevention campaign. Provision of concussion online short courses, currently more than 20,000 completions.
Source: Supplied
Arranged by: Curtin Medical Research Institute
https://orcid.org/0000-0002-4823-8179
-
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
-
Next Generation Condom Contraception, Dr David Shepherd
Dr David Shepherd is a Lead Production Engineer and Materials Specialist at Eudaemon Technologies. His journey began at the University of Wollongong, where he pursued advanced studies and eventually obtained a PhD under the guidance of a distinguished professor. His research initially focused on actuating materials and artificial muscles, particularly centred around hydrogel materials. These early explorations have seamlessly evolved into his current focus on utilising hydrogels in the realm of sexual reproductive health, with a specific emphasis on developing innovative hydrogel condoms.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
